Posted by Michael Wonder on 16 May 2022
FDA rejects anti-depressant seen as possible COVID-19 treatment
16 May 2022 - The FDA declined Monday to authorise a 30 year old generic anti-depressant as a treatment for COVID-19, dealing a major blow to a small group of doctors who have organised around the pill for months, arguing that it could provide a cheap and accessible way to prevent hospitalisations and death both in the U.S. and around the world.
In an unusual two page summary — the FDA does not generally disclose the reasoning behind rejections — regulators said that the doctors failed to provide adequate evidence of effectiveness of fluvoxamine.
